Altamira Therapeutics Announces Launch of Bentrio in Hong Kong by its Partner Nuance Pharma
November 30, 2022 08:07 ET
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Initiative is Nuance’s first step in penetrating Chinese market with BentrioTMDensely populated Hong Kong (7.3 million) remains negatively...
Altamira Therapeutics to Participate at TIDES Europe Oligonucleotide and Peptide Therapeutics Hybrid Event
November 10, 2022 08:47 ET
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Nov. 10, 2022 (GLOBE NEWSWIRE) -- • TIDES Europe Event will be held on November 16-18, 2022, in Vienna, Austria• Company Chief Development Officer, Covadonga Pañeda, Ph.D., to...
Altamira Therapeutics Regains Listing Compliance with NASDAQ Minimum Bid Requirement
November 09, 2022 08:47 ET
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (NASDAQ: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs today...
Data Published in Peer-Reviewed Journal Demonstrate Protective Effects of Altamira’s Bentrio under Controlled Grass Pollen Exposure
November 08, 2022 08:47 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA, Nov. 08, 2022 (GLOBE NEWSWIRE) -- • Publication in International Archives of Allergy and Immunology shows rapid onset and long duration of Bentrio’s protective effects in allergic...
Altamira Therapeutics Announces Reverse Stock Split
October 24, 2022 08:47 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA , Oct. 24, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today...
Altamira Therapeutics Announces Divestiture of Inner Ear Development Assets
October 21, 2022 08:47 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA , Oct. 21, 2022 (GLOBE NEWSWIRE) -- Definitive agreement to sell 90% stake in Company’s Zilentin subsidiary with option to acquire all of Altamira’s remaining inner ear...
Altamira Therapeutics to Participate at RNA Leaders USA Congress
October 13, 2022 08:47 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA , Oct. 13, 2022 (GLOBE NEWSWIRE) -- Event will be held on October 18-19, 2022 in Boston, MASamuel Wickline, MD, Chief Scientific Officer, to present on the advantages of the...
Altamira Therapeutics Continue Bentrio Clinical Trial for Seasonal Allergic Rhinitis in Australia
October 03, 2022 08:47 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA , Oct. 03, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today...
Altamira Therapeutics Re-launches Bentrio in Europe for Allergic Rhinitis
September 27, 2022 08:47 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA , Sept. 27, 2022 (GLOBE NEWSWIRE) -- BentrioTM nasal spray becomes available again in selected European countries Marketing focus is on protection against airborne allergens...
Altamira Therapeutics Completes Enrollment for COVAMID Trial with Bentrio in Acute COVID-19
September 13, 2022 08:47 ET
|
Altamira Therapeutics Ltd
HAMILTON, BERMUDA , Sept. 13, 2022 (GLOBE NEWSWIRE) -- Study has reached extended enrollment target of 160 patients Top-line data read-out expected in Q4-22 Altamira Therapeutics Ltd....